Get the Stockscreener App
4.33
2.70%
-0.12
After Hours:
4.33
Zentalis Pharmaceuticals Inc stock is traded at $4.33, with a volume of 1.21M.
It is down -2.70% in the last 24 hours and up +9.07% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$4.45
Open:
$4.495
24h Volume:
1.21M
Relative Volume:
1.03
Market Cap:
$308.24M
Revenue:
$26.87M
Net Income/Loss:
$-124.13M
P/E Ratio:
-2.4917
EPS:
-1.7378
Net Cash Flow:
$-125.60M
1W Performance:
-15.26%
1M Performance:
+9.07%
6M Performance:
+47.28%
1Y Performance:
+194.56%
1-Day Range:
$4.165
$4.52
1-Week Range:
$4.165
$5.5799
52-Week Range:
$1.212
$6.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
4.33 | 316.78M | 26.87M | -124.13M | -125.60M | -1.7378 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 120.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.84B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.13B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 35.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Resumed | Wells Fargo | Equal Weight |
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
TradingKey - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ZNTL|Zentalis Pharmaceuticals Inc|Price:4.445|Chg%:-0.055 - TradingKey
ZNTL Initiated Coverage by Rodman & Renshaw -- Price Target Anno - GuruFocus
Rodman & Renshaw initiates Zentalis stock with buy on drug potential - Investing.com Canada
ManpowerGroup posts upbeat Q2 earnings, joins Docebo, Zentalis Pharmaceuticals and other big stocks moving higher on Friday - MSN
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally? - Yahoo! Finance Canada
ZENTALIS PHARMACEUTICALS INC : MIZUHO INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $8 - Bitget
What date does Zentalis Pharmaceuticals's (ZNTL) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
ZNTL Jumps As Mizuho Targets Upside On Cancer Drug - StocksToTrade
Mizuho Securities Initiates a Buy Rating on Zentalis Pharmaceuticals (ZNTL) - The Globe and Mail
Zentalis Pharmaceuticals Initiated at Outperform by Mizuho - Moomoo
Mizuho Securities Initiates Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Announces Target Price $8 - Moomoo
Zentalis Pharmaceuticals Announces ESMO 2026 Rapid Oral Presentation of DENALI Overall Survival Data for Azenosertib in Platinum-Resistant Ovarian Cancer - Quiver Quantitative
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026 - GlobeNewswire
Zentalis' Azenosertib Accepted for Rapid ESMO Survival Presentation - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Movin - Benzinga
Mizuho initiates Zentalis Pharmaceuticals stock at Outperform By Investing.com - Investing.com South Africa
Mizuho initiates Zentalis Pharmaceuticals stock at Outperform - Investing.com
ZNTL Initiates Coverage On by Mizuho -- Rating Set to Outperform - GuruFocus
ZNTL Stock Rallies To Near 22-Month Highs – An Analyst Sees Further 56% Upside After A Crucial Trial Update - Stocktwits
Zentalis Pharmaceuticals outlines its oncology focus as Nasdaq-listed biotech - Ad-hoc-news.de
Zentalis Pharmaceuticals (ZNTL) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Zentalis Pharmaceuticals outlines oncology pipeline strategy as clinical programs advance - ad-hoc-news.de
ZNTL Q1 2026 Earnings: Slightly Wider Loss Meets Modest Stock UptickEarnings Quality Score - dars.gov.et
June 2026 Penny Stocks With Promising Potential - Sahm
Zentalis Pharmaceuticals (ZNTL) Rallies 5.21% as Biotech Sector Finds FootingScalping Stock Signals - dars.gov.et
Zentalis Pharmaceuticals Surges 14%: Biotech Stock Breaks Above Key Support ZoneBearish Pattern Stocks - dars.gov.et
Zentalis Pharmaceuticals, Inc.(NasdaqGM: ZNTL) added to Russell 2000 Index - marketscreener.com
Zentalis Pharmaceuticals, Inc.(NasdaqGM: ZNTL) added to Russell 3000E Index - marketscreener.com
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Zentalis Pharmaceuticals, Inc.(NasdaqGM: ZNTL) added to Russell 2500 Value Benchmark - marketscreener.com
ZNTL Q1 2026 Earnings: EPS Miss Weighs on Shares as Pipeline Progress Remains in FocusCost Structure Review - DonanımHaber
Zentalis Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ZNTL) - TradingView
Enterprise value to revenue forward of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL - TradingView
Price to book forward of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL - TradingView
Price to sales forward of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL - TradingView
Zentalis Pharmaceuticals Inc (ZNTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zentalis Pharmaceuticals (ZNTL) Edges Higher as Biotech Sector Sees Mixed SentimentDividend Arbitrage - dars.gov.et
ZNTL Should I Buy - Intellectia AI
Zentalis Shareholders Back Directors, Auditors and Executive Pay - TipRanks
Zentalis (ZNTL) director awarded 57,100 RSUs, boosting holdings to 307,521 shares - Stock Titan
RSU grant boosts Zentalis (ZNTL) director Jan Skvarka's holdings - Stock Titan
Zentalis Pharmaceuticals (ZNTL) director granted 57,100 restricted stock units - Stock Titan
Zentalis (ZNTL) director Enoch Kariuki granted 57,100 restricted stock units - Stock Titan
Zentalis Pharmaceuticals (ZNTL) director awarded 57,100 RSUs - Stock Titan
Zentalis (ZNTL) investors elect directors and ratify Ernst & Young at 2026 meeting - Stock Titan
Zentalis Pharmaceuticals Inc (ZNTL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Institutional Confidence - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):